Amgen (AMGN) Equity Income (2020 - 2025)

Amgen's Equity Income history runs 6 years deep, the most recent figure standing at $10.0 million for Q3 2025.

• In Q3 2025, Equity Income rose 135.71% year-over-year to $10.0 million; the TTM figure through Sep 2025 stood at -$20.0 million (down 17.65% YoY), while the FY2024 annual figure was $10.0 million, up 190.91% from the prior year.
• Equity Income was $10.0 million for Q3 2025 at Amgen, up from -$18.0 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $97.0 million in Q4 2021 to a low of -$305.0 million in Q1 2022.
• Historically, Equity Income has averaged -$31.0 million across 5 years, with a median of -$11.0 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Equity Income sank 671.43% in 2022, then jumped 142.86% in 2024.
• A 5-year view of Equity Income shows it stood at $97.0 million in 2021, then tumbled by 283.51% to -$178.0 million in 2022, then surged by 84.27% to -$28.0 million in 2023, then soared by 96.43% to -$1.0 million in 2024, then jumped by 1100.0% to $10.0 million in 2025.
• The last three Equity Income figures came in at $10.0 million (Q3 2025), -$18.0 million (Q2 2025), and -$11.0 million (Q1 2025), per Business Quant data.